Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine Collapses
Business, Stock ReportsThe psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts Pipeline
Business, Stock ReportsMindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?
The Real Reason Cybin Bought Entheon’s DMT Clinical Trial
Business, Research, Stock ReportsIn a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Business, Stock ReportsCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
Psychedelic Business Spotlight – July 1
Business, News, Stock ReportsThis week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders approve company split; and more!
This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!
Business, News, Stock ReportsThis week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Psychedelic Business Spotlight – June 17
Business, News, Stock ReportsThis week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
Psychedelic Business Spotlight – June 10
Business, Stock ReportsThis week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and more!
Psychedelic Business Spotlight – June 3
Business, Stock ReportsThis week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!
Psychedelic Business Spotlight – May 27
Business, Stock ReportsThis week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon.